Beta Drugs Reports Audited Financial Results for FY26, Targets 80% Own Branded Product Contribution by 2030

Beta Drugs Reports Audited Financial Results for FY26, Targets 80% Own Branded Product Contribution by 2030​

Beta Drugs Limited today announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company reported consolidated total revenues of Rs 396.0 crores for the fiscal year, marking a 7.4% increase from the Rs 368.8 crores recorded in the previous fiscal year.

The consolidated EBITDA stood at Rs 86.9 crores, reflecting an improvement in margins to 22.6% in FY26 compared to 21.1% in FY25.

Key Financial Performance Metrics (FY26 vs FY25)​

The following table summarizes the key financial highlights for the year ended March 31, 2026, compared to the previous fiscal year.


Beta Drugs recorded a net profit of INR 41.5 Crs, resulting in a net margin of 10.8%. This saw a slight decrease compared to INR 42.4 Crs reported in FY25. The company attributed the drop in net profit to higher finance costs associated with Convertible Coupons Debt (CCDs) issued in November 2024, which are scheduled for conversion in May 2026. Management noted that had these CCDs interest costs been excluded, the net profit would have stood at 48 crores, equating to a net margin of 12.5%.

Operational Drivers and Growth Momentum​

The company's branded oncology business continued its strong performance, delivering 20.0% growth. Additionally, the Derma segment maintained healthy growth momentum of 34.8% and achieved monthly break-even status.

The export business showed continued, unabated momentum. Beta recorded a total of 166 registrations in key international export markets. The company highlighted its commitment to quality, citing its expanding list of global accreditations, including COFEPRIS, ANVISA, and EAEU.

Beta Drugs remains positioned as one of the fastest-growing players in the Indian branded oncology pharmaceutical market, actively gaining market share from established competitors. The company’s focus on Research and Development (R&D) has been pivotal, leading to the launch of differentiated products, including Non-Drug Delivery Systems (NDDS) and "first to launch" products in India, thereby strengthening its presence both domestically and internationally.

Strategic Outlook and Vision 2030​

Beta Drugs has set out a comprehensive vision for 2030, targeting accelerated growth and higher operating margins. Under this vision, the company expects high-margin businesses, including its own branded products and export revenues, to contribute over 80% of the total turnover by 2030.

To support its expansion into complex therapies, Beta announced its acquisition of Nivan Lifesciences Private Limited. The company is also reinforcing its commitment to quality by expanding its API facility to achieve backward integration into key intermediates. This move is intended to enhance margins, ensure consistent quality, and reduce reliance on third-party suppliers, offering greater flexibility in an increasingly volatile external environment.

The long-term growth strategy includes leveraging its strong R&D capabilities and differentiated pipeline, which encompasses NDDS and FTL/FFTL platforms. Furthermore, the company expects an EU audit of its formulation plant in Q3 of FY27, which is set to expand multiple end-markets and provide a long runway for growth.

BETA Stock Price Movement​

Shares of Beta Drugs Limited today slipped by 0.55% to close at ₹1403.6. The stock settled with a total traded volume of 15,662 shares.